Pharmaceutical is a biopharmaceutical company dedicated to the discovery and development of a series of histone deacetylase (HDAC) inhibitor programs for oncology and other diseases with high unmet medical needs.

Chairman of the Board

Chief Executive Officer

Special Advisor to the Chairman

Mutations in the BAP1 gene prevent normal protection of p53, a key tumor suppressor. At the same time, overexpression of HDAC8 blocks the transcription of p53 protein, allowing cancer cells to grow unchecked. NBM-BMX is a selective HDAC8 inhibitor designed to restore this critical pathway.

Mutations in the BAP1 gene prevent normal protection of p53, a key tumor suppressor. At the same time, overexpression of HDAC8 blocks the transcription of p53 protein, allowing cancer cells to grow unchecked. NBM-BMX is a selective HDAC8 inhibitor designed to restore this critical pathway.

Hepatocellular Carcinoma：Investigator-Initiated Trial

Mesothelioma：Investigator-Initiated Trial

Advancing a lead program in uveal melanoma (UM) with liver metastasis.

Expansion to novel HDAC8 and other selective HDAC compounds.

Engaging with leading CROs, academic centers, and patient advocacy groups.